ヒストン脱アセチル化酵素阻害剤市場：クラス別、用途別-2025～2030年の世界予測

ヒストン脱アセチル化酵素阻害剤市場は、2023年に164億3,000万米ドルと評価され、2024年には183億2,000万米ドルに達すると予測され、CAGR 11.96％で成長し、2030年には362億5,000万米ドルに達すると予測されています。

ヒストン脱アセチル化酵素阻害剤（HDAC阻害剤）は、ヒストン脱アセチル化酵素の機能を阻害する化合物の一種であり、クロマチン構造の改変と遺伝子発現の制御に関与する酵素です。HDAC阻害剤の主要用途は腫瘍学であり、がん細胞のアポトーシスや細胞周期の停止を誘導する能力を活用します。しかし、エピジェネティックな調節における役割から、その応用範囲は神経疾患や炎症性疾患にも及びます。最終用途の範囲には、主に新規がん治療に注力している製薬会社や、アルツハイマー病やハンチントン病の治療法を模索している研究者が含まれます。HDAC阻害剤の市場成長は主に、がんや神経変性疾患の有病率の増加、標的治療の研究開発への投資の高まりに影響されています。さらに、バイオインフォマティクスとゲノミクスの技術的進歩は、より正確な薬剤設計を可能にすることで市場の可能性を高めています。現在のビジネス機会は、多発性骨髄腫やその他のがんの治療としてFDAに承認されている既存のHDAC阻害剤の適応拡大や、免疫がん治療との併用療法の模索にあります。薬剤耐性、副作用、エピジェネティックな制御の複雑な性質といった課題は、臨床検査に関連する気の遠くなるようなコストとスケジュールとともに、重大なハードルを提示しています。技術革新は、HDAC阻害剤の選択性と治療指数の向上、患者層別化のためのバイオマーカーの開発、創薬プロセスの最適化のためのAIの統合に向けられるのが最善であると考えられます。HDAC阻害剤市場の競争は中程度で、数多くの小規模なバイオテクノロジー企業と大規模な製薬企業が進歩を目指しており、ポートフォリオと能力の拡大を目指す企業による統合や提携の動向は明らかです。企業は、このダイナミックなセグメントで競合を維持するために、開発の加速や有望なリード化合物の導入のための戦略的提携に価値を見出すことができると考えられます。

市場力学：急速に進化するヒストン脱アセチル化酵素阻害剤市場の主要市場洞察を公開

ヒストン脱アセチル化酵素阻害剤市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 効果的な治療法の必要性と相まって、がんの罹患率の増加
  • 慢性疾患の予後、治療、診断への応用の増加
  • 気分を安定させ、抗てんかん作用を持つことから、精神科と神経科からのニーズの高まり
• 市場抑制要因
  • 人材の認知度の低さと償還ポリシーの欠如
  • 原材料の高コストと訓練された専門家の不足
• 市場機会
  • 先端技術の採用とメーカー・企業間の協力関係の高まり
  • 政府と民間組織による医薬品開発への投資の増加
• 市場課題
  • 製造に関する厳しい規制と、毒性などの副作用の可能性

ポーターのファイブフォース：ヒストン脱アセチル化酵素阻害剤市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ヒストン脱アセチル化酵素阻害剤市場における外部からの影響の把握

外部マクロ環境要因は、ヒストン脱アセチル化酵素阻害剤市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：ヒストン脱アセチル化酵素阻害剤市場における競合情勢の把握

ヒストン脱アセチル化酵素阻害剤市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：ヒストン脱アセチル化酵素阻害剤市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ヒストン脱アセチル化酵素阻害剤市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：ヒストン脱アセチル化酵素阻害剤市場における成功への道筋を描く

ヒストン脱アセチル化酵素阻害剤市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がんの発生率の増加と効果的な治療法の必要性
    • 慢性疾患の予後、治療、診断への応用が増加
    • 気分安定作用と抗てんかん作用により精神科と神経科からの需要が高まっている
  • 抑制要因
    • 人材の認識不足と補償ポリシーの欠如
    • 原材料の高コストと訓練を受けた専門家の不足
  • 機会
    • 先進技術の導入とメーカーや企業間の連携の拡大
    • 政府と民間組織による医薬品開発への投資の増加
  • 課題
    • 製造に関する厳格な規制と毒性などの副作用の可能性
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 ヒストン脱アセチル化酵素阻害剤市場：クラス別

• イントロダクション
• クラスI HDAC
• クラスII HDAC
• クラスIII HDAC

第7章 ヒストン脱アセチル化酵素阻害剤市場：用途別

• イントロダクション
• 中枢神経系疾患
• 神経学
• 腫瘍学

第8章 南北アメリカのヒストン脱アセチル化酵素阻害剤市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋のヒストン脱アセチル化酵素阻害剤市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのヒストン脱アセチル化酵素阻害剤市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AstraZeneca PLC
• Bristol Myers Squibb Company
• Celleron Therapeutics Ltd.
• Eisai Co., Ltd.
• Karyopharm Therapeutics Inc.
• MEI Pharma Inc.
• Merck KGaA
• Midatech Pharma PLC
• Novartis AG
• Oncolys BioPharma Inc.
• Regenacy Pharmaceuticals, Inc.
• Shenzhen Chipscreen Biosciences Co., Ltd.
• Spectrum Pharmaceuticals, Inc.
• Syndax Pharmaceuticals, Inc.
• Tokyo Chemical Industry Co. , Ltd.

LIST OF FIGURES

• FIGURE 1. HISTONE DEACETYLASE INHIBITORS MARKET RESEARCH PROCESS
• FIGURE 2. HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. HISTONE DEACETYLASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. HISTONE DEACETYLASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HISTONE DEACETYLASE INHIBITORS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HISTONE DEACETYLASE INHIBITORS MARKET DYNAMICS
• TABLE 7. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I HDACS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II HDACS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III HDACS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. CANADA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 23. CANADA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 35. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. INDIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 37. INDIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. ITALY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 72. ITALY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. POLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 80. POLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. QATAR HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 82. QATAR HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. HISTONE DEACETYLASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 102. HISTONE DEACETYLASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

The Histone Deacetylase Inhibitors Market was valued at USD 16.43 billion in 2023, expected to reach USD 18.32 billion in 2024, and is projected to grow at a CAGR of 11.96%, to USD 36.25 billion by 2030.

Histone deacetylase inhibitors (HDAC inhibitors) are a class of compounds that interfere with the function of histone deacetylases, enzymes implicated in modifying chromatin structure and regulating gene expression. Their primary necessity lies in oncology, where they are leveraged for their ability to induce apoptosis and cell cycle arrest in cancer cells. However, their application scope extends to neurological and inflammatory disorders, given their role in epigenetic modulation. The end-use scope primarily includes pharmaceutical companies focusing on novel cancer therapies and researchers exploring therapeutics for Alzheimer's and Huntington's diseases. Market growth for HDAC inhibitors is primarily influenced by an increasing prevalence of cancer and neurodegenerative disorders, coupled with heightened investment in research and development of targeted therapies. Additionally, technological advancements in bioinformatics and genomics bolster market potential by enabling more precise drug design. Current opportunities lie in expanding labels for existing FDA-approved HDAC inhibitors to treat multiple myeloma and other cancers, as well as exploring combination therapies alongside immuno-oncology agents. Challenges such as drug resistance, adverse effects, and the intricate nature of epigenetic regulation present significant hurdles, alongside the daunting costs and timelines associated with clinical trials. Innovation might best be directed toward improving the selectivity and therapeutic index of HDAC inhibitors, developing biomarkers for patient stratification, and integrating AI for optimizing drug discovery processes. The nature of the HDAC inhibitor market is moderately competitive with numerous small biotech firms and larger pharmaceutical companies striving for advancements, and a trend toward consolidation and collaboration evident as entities seek to expand their portfolios and capabilities. Businesses may find value in strategic alliances for accelerated development and in-lisencing promising lead compounds to stay competitive in this dynamic field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Histone Deacetylase Inhibitors Market

The Histone Deacetylase Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing incidence of cancer coupled with need for effective treatment therapies
  • Increasing application in prognosis, treatment and diagnosis of chronic diseases
  • Rising need from psychiatry and neurology attributed to their mood stabilizing and anti-epileptic properties
• Market Restraints
  • Dearth of awareness among people and lack of reimbursement policies
  • High cost of raw material and lack of trained professionals
• Market Opportunities
  • Rising adoption of advanced technologies and collaboration among manufacturers and companies
  • Increasing investment for drug development from government and private organizations
• Market Challenges
  • Strict mandates for the production and probable side effects such as toxicity

Porter's Five Forces: A Strategic Tool for Navigating the Histone Deacetylase Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Histone Deacetylase Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Histone Deacetylase Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Histone Deacetylase Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Histone Deacetylase Inhibitors Market

A detailed market share analysis in the Histone Deacetylase Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Histone Deacetylase Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Histone Deacetylase Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Histone Deacetylase Inhibitors Market

A strategic analysis of the Histone Deacetylase Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Histone Deacetylase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bristol Myers Squibb Company, Celleron Therapeutics Ltd., Eisai Co., Ltd., Karyopharm Therapeutics Inc., MEI Pharma Inc., Merck KGaA, Midatech Pharma PLC, Novartis AG, Oncolys BioPharma Inc., Regenacy Pharmaceuticals, Inc., Shenzhen Chipscreen Biosciences Co., Ltd., Spectrum Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., and Tokyo Chemical Industry Co. , Ltd..

Market Segmentation & Coverage

This research report categorizes the Histone Deacetylase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Class, market is studied across Class I HDACs, Class II HDACs, and Class III HDACs.
• Based on Application, market is studied across Central Nervous System Disorders, Neurology, and Oncology.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidence of cancer coupled with need for effective treatment therapies
    • 5.1.1.2. Increasing application in prognosis, treatment and diagnosis of chronic diseases
    • 5.1.1.3. Rising need from psychiatry and neurology attributed to their mood stabilizing and anti-epileptic properties
  • 5.1.2. Restraints
    • 5.1.2.1. Dearth of awareness among people and lack of reimbursement policies
    • 5.1.2.2. High cost of raw material and lack of trained professionals
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising adoption of advanced technologies and collaboration among manufacturers and companies
    • 5.1.3.2. Increasing investment for drug development from government and private organizations
  • 5.1.4. Challenges
    • 5.1.4.1. Strict mandates for the production and probable side effects such as toxicity
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Histone Deacetylase Inhibitors Market, by Class

• 6.1. Introduction
• 6.2. Class I HDACs
• 6.3. Class II HDACs
• 6.4. Class III HDACs

7. Histone Deacetylase Inhibitors Market, by Application

• 7.1. Introduction
• 7.2. Central Nervous System Disorders
• 7.3. Neurology
• 7.4. Oncology

8. Americas Histone Deacetylase Inhibitors Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Histone Deacetylase Inhibitors Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Histone Deacetylase Inhibitors Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AstraZeneca PLC
• 2. Bristol Myers Squibb Company
• 3. Celleron Therapeutics Ltd.
• 4. Eisai Co., Ltd.
• 5. Karyopharm Therapeutics Inc.
• 6. MEI Pharma Inc.
• 7. Merck KGaA
• 8. Midatech Pharma PLC
• 9. Novartis AG
• 10. Oncolys BioPharma Inc.
• 11. Regenacy Pharmaceuticals, Inc.
• 12. Shenzhen Chipscreen Biosciences Co., Ltd.
• 13. Spectrum Pharmaceuticals, Inc.
• 14. Syndax Pharmaceuticals, Inc.
• 15. Tokyo Chemical Industry Co. , Ltd.